RAF1 and hereditary clear cell renal cell carcinoma: Additionally, the results of clinical trial analyses of sorafenib in renal cell carcinoma and melanoma have not provided sufficient information to conclude that the clinical value is associated with inhibition of the RAF/MEK/ERK signaling pathway [8].